The members of the Translational Research and Innovative Medicine Laboratory (TrimLAB) proudly congratulate Assoc. Prof. Dr. Praopim Limsakul, Principal Investigator of TrimLAB, on the successful grant of a United States Patent (U.S. Patent No. US 12,516,315 B2) for the invention entitled "Genetically Engineered Immune Effector Cells Comprising R-Phycoerythrin-Targeting Receptor Conjugated Chimeric Antigen Receptor." The patent was jointly invented by Yingxiao Wang, Praopim Limsakul, and Yiqian Wu, recognizing their collaborative efforts in advancing next-generation cancer immunotherapy.
The patented technology introduces a novel universal CAR-T cell platform that enables a single CAR-T cell product to be redirected toward different cancer targets simply by changing the PE-conjugated antibody used. This modular design eliminates the need to engineer a new CAR-T cell for each target, offering a more flexible and potentially cost-effective approach to personalized cancer treatment while simplifying the development of CAR-T therapies.
This achievement reflects the power of international collaboration in driving biomedical innovation. TrimLAB sincerely thanks Prof. Dr. Yingxiao Wang and Dr. Yiqian Wu for their invaluable partnership and scientific contributions throughout this work. Together, their collaborative research has resulted in a technology with promising potential to advance the field of cancer immunotherapy.
We extend our warmest congratulations to Assoc. Prof. Dr. Praopim Limsakul and all the inventors on this remarkable accomplishment. We look forward to seeing this innovation contribute to future translational research and ultimately improve the lives of patients worldwide.